ArticleHead and neck pathology2025
Reticular and Myxoid Variant of EBV-positive Nasopharyngeal Carcinoma Mimicking Salivary Gland Tumors: A Case Series.
Article in Head and neck pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Harnessing the immune microenvironment: advances in nasopharyngeal carcinoma immunotherapy.Cell death discovery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to characterize the rare morphological variant of nasopharyngeal carcinoma known as reticular and myxoid nasopharyngeal carcinoma (RMNK-NPC), which poses diagnostic challenges due to its resemblance to salivary gland tumors. We seek to detail its histopathological and immunohistochemical features, clarify differential diagnoses, and evaluate clinical outcomes.
methodsCases of RMNK-NPC were retrospectively identified from pathology consultation archives and multidisciplinary conference records in Taiwan. Histopathological features, including results of previously performed immunohistochemical stains and Epstein-Barr virus-encoded RNA (EBER) in situ hybridization, were reviewed by three pathologists. Relevant clinical information and imaging findings were collected when available. A literature search was conducted to identify previously reported cases with similar histological features.
resultsThe cohort included eight patients (7 males, 1 female; median age 65.5 years). Clinical presentations included advanced-stage tumors with lymph node metastases in seven patients and distant metastasis in two patients. All tumors exhibited myxoid stroma with reticular, trabecular, and cord-like arrangements of epithelioid to spindle cells, with transition to non-keratinizing squamous cell carcinoma (NKSCC) in three cases. Immunohistochemistry showed consistent positivity for pan-cytokeratin and squamous markers, while other myoepithelial markers were mostly negative, except SOX10. EBER ISH showed strong nuclear positivity in most cases, confirming EBV association. Limited follow-up data for four patients who received chemoradiotherapy showed stable disease at 3-4 months in two. The other two patients died at 42 and 108 months, respectively, from unrelated causes, with no recurrence observed.
conclusionRMNK-NPC represents an EBV-associated NPC with unique histomorphology that overlaps with salivary gland tumors. Accurate diagnosis relies on comprehensive immunohistochemical panels and EBER ISH. Awareness of this entity is crucial to avoid misdiagnosis and guide appropriate treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.